Sensorion

Sensorion Interest Expense

The Interest Expense of Sensorion (ALSEN.PA) as of Oct 9, 2026 is 2.56 M EUR. In the previous year, Interest Expense was 544,200.00 EUR — a change of 369.50% (higher).

Interest Expense

2.56 MEUR

YoY

369.50%

Last updated:

Interest Expense of Sensorion is 2024 2.56 M EUR. Interest Expense of Sensorion was 2023 544,200.00 EUR. It decreases by 369.50% higher compared to the previous year.

The Sensorion Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2017
-170,400.00 EUR
Jan 1, 2018
-124,300.00 EUR
Jan 1, 2019
-1.28 M EUR
Jan 1, 2020
-88,900.00 EUR
Jan 1, 2021
-112,200.00 EUR
Jan 1, 2022
-72,400.00 EUR
Jan 1, 2023
544,200.00 EUR
Jan 1, 2024
2.56 M EUR
The Sensorion Interest Expense history
YEARInterest ExpenseYoY
2.56 MEUR+369.50%
544,200.00EUR-851.66%
-72,400.00EUR-35.47%
-112,200.00EUR+26.21%
-88,900.00EUR-93.07%
-1.28 MEUR+931.46%
-124,300.00EUR-27.05%
-170,400.00EUR-58.65%
-412,100.00EUR+422.97%
-78,800.00EUR-63.70%
-217,100.00EUR—
Access this data via the Eulerpool API
Get Free API Key

Sensorion Stock analysis

What does Sensorion do? The company Sensorion SA is a French biotechnology company that specializes in developing innovative therapies for hearing and balance disorders. It was founded in 2009 and is headquartered in Montpellier. Sensorion SA's business model is based on researching and developing new drugs that can be used to treat inner ear diseases. These diseases often have severe effects on the quality of life and social interaction of those affected and represent a significant unmet medical need. Sensorion SA aims to develop innovative and effective therapies to address this need. The company specializes in two main areas: hearing disorders and balance disorders. In the field of hearing disorders, Sensorion SA focuses on developing drugs to treat sensorineural hearing loss. These disorders can be caused by various factors such as aging, noise exposure, or genetic predisposition and affect the inner ear. Sensorion SA has a promising pipeline of drugs in clinical development based on different mechanisms of action. These drugs aim to protect the inner ear and restore hearing function. In the field of balance disorders, Sensorion SA focuses on developing new drugs to treat dizziness and vestibular disorders. These disorders can be caused by factors such as aging, medications, or neurological diseases and affect the balance system in the inner ear. Sensorion SA also has a promising pipeline of drugs in clinical development in this area. Sensorion SA's products are not yet available on the market as they are still in development and undergoing clinical trials. However, the company works closely with academic and industry partners to test and validate its drugs. The development of new drugs is a lengthy and costly process that can take many years. However, Sensorion SA is confident that its therapies have the potential to improve the lives of many people. Overall, Sensorion SA has a promising business model based on the development of innovative therapies for hearing and balance disorders. The company has a promising pipeline of drugs in clinical development and works closely with partners to test and validate its products. If successful, their drugs could have a significant impact on the lives of people suffering from these diseases. Sensorion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sensorion stock

Interest Expense of Sensorion is 2.56 M EUR in 2024.

Interest Expense of Sensorion changed from 544,200.00 EUR to 2.56 M EUR, representing a 369.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense Sensorion since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's Sensorion historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Income Statement — Sensorion

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Sensorion